Third-Line Treatment Options for Metastatic Colorectal Cancer - Episode 7
Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment
Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.
- How frequently are you observing hypertension when treating your patients with trifluridine-tipiracil plus bevacizumab? What is your monitoring and management strategy for hypertension?
- How often do you see patients with hepatic or renal impairment in your clinical practice? What is your dosing strategy for TAS-102 plus bevacizumab for those who have hepatic or renal impairment?
- What are some common toxicities associated with fruquintinib? How do you manage patients who may develop hypertension, hand-foot syndrome, or hepatotoxicity?
- What are some common toxicities associated with regorafenib? How does your clinic manage potential toxicities seen with regorafenib, like hand-foot syndrome?
Related Content:
